NAT MED: Is serum IL-8 elevated associated with increased neutofletosofa in tumors and reduced clinical benefits of immunocheckpoint inhibitors?
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Previous studies have shown a relationship between serum leukocyte interleukin-8 (IL-8) levels and tumor neutrophil leaching, as well as poor prognostication in patients with advanced cancerrecently, researchers conducted a large-scale retrospective analysisThe results showed that in 1,344 patients with advanced cancer who received nivolumab and/or ipilimumab, everolimus or docetaxel in Phase 3 clinical trials, elevated serum IL-8 levels were associated with poor prognosisthis reveals the importance of assessing serum IL-8 levels in identifying adverse tumor immunobiology, and can serve as a separate biomarker for patients receiving immunocheckpoint inhibitors
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
